Abhinav Khare

Abhinav Khare

Auto-generated profile, based on publicly available information

Abhinav Khare

All India Institute of Medical Sciences

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Clinical Infection in Practice
Verified
Journal Article
Open access
AVAmogh Verma
Amogh Verma
AAAyush Anand
Ayush Anand
ASAjeet Singh
Ajeet Singh
AKAbhinav Khare
Abhinav Khare
ANAhmad Neyazi
Ahmad Neyazi
PSPrakasini Satapathy
Prakasini Satapathy

21 April 2025 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
MBMainak Bardhan
Mainak Bardhan
MMMuneeb Ahmad Muneer
Muneeb Ahmad Muneer
AKAbhinav Khare
Abhinav Khare
RSRushita Minesh Shah
Rushita Minesh Shah
AKAnmol Kaur
Anmol Kaur
ZCZhijian Chen
Zhijian Chen
Glioblastoma (GBM), a highly malignant brain tumor, has a poor prognosis despite standard treatments like surgery, chemotherapy, and radiation. Glioblastoma stem cells (GSCs) play a critical role in recurrence and therapy resistance. Stem cell-based therapies have emerged as innovative approaches, leveraging the tumor-targeting abilities of stem cells to deliver treatments directly to GBM. This review focuses on using intact stem cells or subtypes for GBM therapy, excluding antigenic characteristics. The stem cell-based therapies explored include neural, mesenchymal, glioblastoma, hematopoietic and adipose-derived stem cells that have been investigated in both clinical and preclinical settings. A systematic search in PubMed, EMBASE, ClinicalTrials.gov, and Scopus had identified research up until January 2024. Key mechanisms reviewed include immune modulation, angiogenesis inhibition, and apoptosis induction. Discussion of completed and ongoing trials include emphasis on safety, efficacy, challenges, and study design limitations. Stem cell-based therapies hold promise for treating GBM by targeting GSCs and improving treatment outcomes. Despite some potential advantages, challenges such as tumorigenesis risks, delivery complexities, and sustained therapeutic effects persist. Future research should prioritize optimizing stem cell modifications, combining them with current treatments, and conducting large-scale trials to ensure safety and efficacy. Integrating stem cell therapies into GBM treatment could provide more effective and less invasive options for patients.